Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 3:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Calcipotriene Clear all
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

NCT04642287
View directory record Official record
Conditions
Immunotherapy, Cutaneous Squamous Cell Carcinoma, Actinic Keratoses, Organ Transplant Recipients, Skin Cancer
Interventions
Calcipotriol Only Product in Cutaneous Dose Form, Vaseline, Topical 5FU
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Sep 23, 2026, 3:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis

NCT03441789
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Enstilar, Vehicle, Otezla
Drug
Lead sponsor
L.H. Kircik, M.D.
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Sacramento, California • Louisville, Kentucky • Rockville, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 23, 2026, 3:09 PM EDT
Completed Phase 1 Interventional

Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis

NCT01582932
View directory record Official record
Conditions
Psoriasis
Interventions
Calcipotriene 0.005% Foam
Drug
Lead sponsor
Mayne Pharma International Pty Ltd
Industry
Eligibility
2 Years to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
36
States / cities
Birmingham, Alabama • Rogers, Arkansas • Encino, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 23, 2026, 3:09 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients

NCT05699603
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Biopsy, Calcipotriene, Fluorouracil
Procedure · Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
Tucson, Arizona • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 23, 2026, 3:09 PM EDT
Completed Phase 2 Interventional Results available

An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects

NCT02038569
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
LEO 80185 gel
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 17 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
San Diego, California • Tampa, Florida • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 23, 2026, 3:09 PM EDT
Completed Phase 4 Interventional

Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis

NCT00437255
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Clobetasol Propionate, 0.05%, Calcipotriene and betamethasone dipropionate ointment
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 80 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Fridley, Minnesota • Austin, Texas • Bryan, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 23, 2026, 3:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream

NCT03899064
View directory record Official record
Conditions
Photoallergy
Interventions
Induction: Application of MC2-01 Cream, irradiation, Induction: Application of MC2-01 Cream, no irradiation, Induction: Applications of MC2-01 vehicle, irradiation, Induction: Applications of MC2-01 vehicle, no irradiation, Challenge: Application of MC2-01 Cream, irradiation, Challenge: Application of MC2-01 Cream, no irradiation, Challenge: Applications of MC2-01 vehicle, irradiation, Challenge: Applications of MC2-01 vehicle, no irradiation, Challenge: Control, irradiation
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 23, 2026, 3:09 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

NCT03448081
View directory record Official record
Conditions
Pruritus, Psoriasis
Interventions
SNA-120, Placebo, Calcipotriene
Drug
Lead sponsor
Sienna Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
17
States / cities
Anniston, Alabama • Mobile, Alabama • Fountain Valley, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Sep 23, 2026, 3:09 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies

NCT00689481
View directory record Official record
Conditions
Psoriasis
Interventions
U0267 Foam, Vehicle foam
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
12
States / cities
Mobile, Alabama • Fremont, California • Ormond Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Sep 23, 2026, 3:09 PM EDT
Completed Not applicable Interventional

Topical Vitamin D in Acute Graft Versus Host Disease of the Skin

NCT03093805
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Calcipotriene
Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Months to 35 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 23, 2026, 3:09 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Combination 5-FU / Calcipotriene Cream for SCCIS/SCC

NCT04839731
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
Combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream, Nourivan Base Cream
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Sep 23, 2026, 3:09 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris

NCT00817219
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcipotriene plus betamethasone dipropionate ointment
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Fremont, California • San Diego, California • Maitland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 23, 2026, 3:09 PM EDT
Completed Phase 2 Interventional

Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis

NCT00625326
View directory record Official record
Conditions
Plaque-type Psoriasis
Interventions
COL-121, 50 µg/g Calcipotriene Ointment, Placebo
Drug
Lead sponsor
Deltanoid Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Sep 23, 2026, 3:09 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis

NCT01563068
View directory record Official record
Conditions
Psoriasis
Interventions
Calcipotriene 0.005% Foam
Drug
Lead sponsor
Mayne Pharma International Pty Ltd
Industry
Eligibility
12 Years to 16 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
San Diego, California • Ormond Beach, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 23, 2026, 3:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients

NCT03848871
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Enstilar
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Sep 23, 2026, 3:09 PM EDT
Recruiting Phase 3 Interventional

A Pilot Clinical Trial Comparing Topical Fluorouracil to Fluorouracil Plus Calcipotriene Field Treatments in Patients With Multiple Actinic Keratoses

NCT06851507
View directory record Official record
Conditions
Multiple Actinic Keratoses
Interventions
Fluorouracil 5-FU, Fluorouracil/Calcipotriene
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 23, 2026, 3:09 PM EDT
Completed Phase 4 Interventional

Enstilar in Combination With Biologic Agents

NCT03080545
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar 0.005%-0.064% Topical Foam
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Sep 23, 2026, 3:09 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Combination Topical Therapy for Treatment of Scalp Actinic Keratoses

NCT03996252
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Calcipotriene 0.005% Foam, Efudex 5% Topical Cream
Drug
Lead sponsor
Tulane University
Other
Eligibility
40 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 6, 2020 · Synced Sep 23, 2026, 3:09 PM EDT
Completed Phase 4 Interventional Results available

Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

NCT03506477
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis
Interventions
Enstilar® foam, Vehicle foam
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 23, 2026, 3:09 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis

NCT04571151
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
LEXETTE 0.05% Topical Foam, Sorilux 0.005 % Topical Foam, Vehicle Foam
Drug · Other
Lead sponsor
Skin Sciences, PLLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Sep 23, 2026, 3:09 PM EDT
Withdrawn Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Mild to Moderate Psoriatic Fingernail/s

NCT03079973
View directory record Official record
Conditions
Nail Psoriasis
Interventions
P-3073 (calcipotriene 0.005%), Vehicle of P-3073
Drug
Lead sponsor
Polichem S.A.
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Sep 23, 2026, 3:09 PM EDT
Completed Early Phase 1 Interventional

Actinic Keratosis Study

NCT02019355
View directory record Official record
Conditions
Actinic Keratosis
Interventions
5-fluorouracil 5% cream, Calcipotriol 0.005% ointment, Vaseline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Sep 23, 2026, 3:09 PM EDT
Completed Phase 3 Interventional

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

NCT03331523
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Calcipotriene/Betamethasone Dipropionate, Taclonex®, Placebo
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
31
States / cities
Encinitas, California • Fremont, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Sep 23, 2026, 3:09 PM EDT
Completed Phase 1 Interventional

Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test

NCT03004339
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
SOR007 Ointment 2.0%, SOR007 Ointment 1.0%, SOR007 Ointment 0.3%, SOR007 Ointment 0.15%, SOR007 Ointment Placebo, Taclonex® Ointment
Drug
Lead sponsor
DFB Soria, LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 23, 2026, 3:09 PM EDT